Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | CKS1B | P61024 | 1/20 | 0.38 |
| ▸ | SKP1 | P63208 | 1/20 | 0.38 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6324400 | 0.89 | CHRNB2 (0.53) | CHRNB2CHRNA7CHRNA4USP30GPR119 | |
| SCHEMBL6329173 | 0.87 | CHRNB2 (0.45) | CHRNB2CHRNA7CHRNA4USP30GPR119 | |
| SCHEMBL10256688 | 0.81 | GPR119 (0.46) | USP30GPR119HDAC1HDAC2PIK3CA | |
| SCHEMBL31173949 | 0.81 | GPR119 (0.46) | USP30GPR119HDAC1HDAC2PIK3CA | |
| SCHEMBL6330089 | 0.80 | GPR119 (0.45) | CHRNB2CHRNA7CHRNA4USP30GPR119 | |
| SCHEMBL6323850 | 0.80 | HPGDS (0.38) | USP30GPR119ADORA2A | |
| SCHEMBL22523841 | 0.77 | GPR119 (0.52) | GPR119HDAC1HDAC2PDE10A | |
| SCHEMBL12005457 | 0.77 | GPR119 (0.52) | GPR119HDAC1HDAC2PDE10A | |
| SCHEMBL29723219 | 0.77 | GPR119 (0.52) | GPR119HDAC1HDAC2PDE10A | |
| SCHEMBL6324657 | 0.77 | HPGDS (0.53) | CHRNB2CHRNA7CHRNA4USP30GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065178-A1 | Substituted diazabicycloakane derivatives | ABBOTT LABORATORIES | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065178-A1 | Substituted diazabicycloakane derivatives | CHRNA7, CHRNA1, CHRNA5 | CHRNB2 12/4885CHRNA7 1/4885CHRNA4 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.